Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Time Posted：2024-03-21 18:00
On March 20, 2024, HealthGen Biotech Group and Bayer signed an exclusive license agreement for the development, commercialization, and production of a small molecule inhibitor in China. This is also the first time HealthGen has introduced an innovative drug pipeline in the respiratory field from a leading global multinational company.
Time Posted：2024-03-08 14:15
In recent years, with the continuous increase in the number of pediatric patients in China, the market demand for pediatric drugs has been growing. However, there is a shortage of pediatric-specific drugs, and the lack of appropriate dosage forms and specifications, as well as the missing information on pediatric drug use in drug instructions, are still quite common.
Time Posted：2024-01-27 09:30
On January 26, 2024, Healthy Yuan Pharmaceutical Group made another breakthrough in its innovative drug R&D layout. It reached a cooperation agreement with Tongbo'an Bio for the exclusive rights in mainland China to BA2101, a long-acting anti-IL-4Rα monoclonal antibody injection for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
Time Posted：2024-01-26 18:15
On January 24, 2024, Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Joincare"), an innovative research-oriented comprehensive pharmaceutical group, and Jiangsu Qunxin Biopharmaceutical Co., Ltd. (hereinafter referred to as "Qunxin Bio"), focusing on biological therapies for autoimmune and allergic diseases, jointly announced that the two parties have reached a strategic cooperation on the monoclonal antibody QX008N and signed an exclusive license agreement for the China region (including Hong Kong and Macao).
Time Posted：2024-01-23 16:48
Recently, HealthGen (600380.SH) disclosed its "Investor Relations Activity Record Table for December 2023 and January 2024", which shows that 31 institutions have conducted on-site investigations of HealthGen since December last year. Public information indicates that many mainstream institutions have long been paying attention to the company's dynamics and are optimistic about its future development and investment value.
Open your arms to embrace the future - Health Spring 2024 New Year's party successfully held
Time Posted：2024-01-18 14:21
2023 has come to a successful close, and 2024 quietly unfolds. At the annual meeting, we gathered together, and HealthGen ignited the journey of the new year with joyous reunion. Looking back, HealthGen, with innovation at its core, has achieved success through unity and hard work, resulting in a diversified R&D pipeline. Looking ahead, HealthGen, with patients at its center, will continue to forge ahead on the path of innovation, writing a more glorious new chapter. For health, for tomorrow, we make good medicine with care and dedication.
Time Posted：2023-12-30 11:21
On December 29, 2023, the 2023 Capital Market Crystal Ball Award list, initiated by the Securities Market Weekly, was officially released. HealthGen (600380.SZ) stood out from a number of participating listed companies, winning the "2023 Most Investment Value Listed Company" award, thanks to its core driving force of outstanding independent R&D capabilities.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.